Metabolic risks and effects of atypical antipsychotic treatment

J Clin Psychiatry. 2007 Oct;68(10):e24. doi: 10.4088/jcp.1007e24.

Abstract

Weight gain and the associated increased risk of diabetes and cardiovascular disease may be problems for individuals who receive long-term treatment with atypical antipsychotics. Atypical antipsychotics differ in their propensity to cause obesity and other metabolic disturbances. If a patient gains substantial weight while taking atypical antipsychotics, the physician should consider switching him or her to a drug with a lower risk of weight gain. The physician should also address patient lifestyle issues such as a poor diet and lack of exercise.

MeSH terms

  • Antipsychotic Agents / adverse effects*
  • Basal Ganglia Diseases / chemically induced*
  • Basal Ganglia Diseases / diagnosis
  • Education, Medical, Continuing*
  • Humans
  • Obesity / chemically induced*
  • Patient Compliance / statistics & numerical data
  • Risk Factors
  • Schizophrenia / drug therapy*

Substances

  • Antipsychotic Agents